PMC:7228307 / 41489-41938
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 690 | 74-78 | Gene | denotes | FcγR | Gene:2213 |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T358 | 110-114 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T745 | 40-50 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activating |
| T746 | 52-53 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
| T747 | 74-76 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
| T748 | 110-114 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
| T749 | 120-121 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
| T750 | 205-213 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
| T751 | 249-250 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
| T752 | 363-364 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T217 | 101-109 | Chemical | denotes | effector | http://purl.obolibrary.org/obo/CHEBI_35224 |
LitCovid-sample-PD-IDO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T211 | 110-114 | http://purl.obolibrary.org/obo/CL_0000000 | denotes | cell |
LitCovid-sample-Pubtator
| Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
|---|---|---|---|---|---|
| 690 | 74-78 | Gene | denotes | FcγR | Gene:2213 |
LitCovid-sample-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T234 | 0-449 | Sentence | denotes | Thus, the relative contributions of the activating (A) and inhibitory (I) FcγR to the response by an effector cell, the A‐to‐I ratio, may be an important determinant in clinical outcome of therapeutic mAb activity,76, 81, 82 that is, the higher the A‐to‐I ratio, the greater the proinflammatory response induced by the therapeutic mAb or conversely the lower the A‐to‐I ratio, the greater the inhibition or dampening of the proinflammatory response. |
LitCovid-sample-PD-FMA
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T357 | 110-114 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T234 | 0-449 | Sentence | denotes | Thus, the relative contributions of the activating (A) and inhibitory (I) FcγR to the response by an effector cell, the A‐to‐I ratio, may be an important determinant in clinical outcome of therapeutic mAb activity,76, 81, 82 that is, the higher the A‐to‐I ratio, the greater the proinflammatory response induced by the therapeutic mAb or conversely the lower the A‐to‐I ratio, the greater the inhibition or dampening of the proinflammatory response. |